For Alexander Fleming, leaving a petri dish out in the air led to his now famous discovery of antibiotics. For Madeline Lancaster, leaving stem cells in a shaker led to the discovery of a new model for neuroscience: brain organoids. These blobs of tissue, grown from human stem cells, resemble some of the essential parts of the human brain. Although they are as small as apple seeds, brain organoids may hold the key to understanding one of lifes great mysteries: the human brain.
Our brain is, arguably, the organ that most makes humans what we are. Our cerebral cortex, the outermost layer of the brain, underpins human cognition. When things go wrong in the cerebral cortex, either as we develop or as we age, this can cause neurological or psychiatric diseases. Neuroscientists have been trying to understand brain development and disease, but they have run into a pretty basic problem: We (usually) cannot collect brain tissue from living people. So neuroscientists arelimitedto studying tissue that is donated by those who have died or observing a living brain behave in an MRI.
To help fill in the gaps in our knowledge of the brain, scientists have turned to the proverbial lab rats (which are actually mice). Mice, rats, primates, and other animals have given scientists the chance to tease apart the roles of genes, molecules, and cells in brain development and disease. Some important insights were gained from these animals. Genetically engineered mice helped researchers understand how a protein called alpha-synucleincan misfold and clump together in theParkinsons-diseased brain, potentially injuring nerve cells. Research intoAlzheimers disease got a boost by mice that were genetically engineered to have mutations linked to Alzheimers. These mice have helped scientists understand how misfolded beta-amyloid proteins stick together in plaques in the brain, a hallmark of the disease.
But a mouse is not a human: mice do not behave as humans do; mouse brains are simpler than human brains; and the mouse genome is not the human genome. Researchers argue that modified mice or other animals do not reflect the complexity of humans, let alone the complexity of neurological or psychiatric conditions. For many conditions, researchers do not even know which gene defects are part of the underlying cause. Instead of creating a mouse that has the same gene defect as that found in human patients, researchers have had to make do with animal models that behave similarly to humans.
In one test for depression-like behavior, researchers hold mice upside down by their tail and measure how long they struggle against it. Mice that give up sooner are judged to show greater despair. But researchers are rightly skeptical. We can make models by challenging mice in different ways and looking at their behavior but its not at all clear that these animals have the same disease that we do, the neuroscientist Fred H. Gage, President of the Salk Institute for Biological Studies,said.
What then? Four millimeter brain organoids might seem an unlikely source for finding therapeutic breakthroughs for complex diseases. But much hope has been put into them since Madeline Lancasterpresented the first such minibrains in 2013. As with many scientific developments, her discovery had an element of serendipity, but cant be reduced to it.
Lancaster, then a postdoc in a Vienna laboratory, wanted to understand how developing brain cells switch from dividing, when they make more of themselves, to differentiation, when they turn into neurons or glia cells. To start off, Lancaster used techniques to coax stem cells, which can develop into pretty much any tissue, towards becoming neurons. But she had also been intrigued by the success of another research team, which grew mini-guts in Matrigel, a gelatinous protein mixture. So once Lancaster had coaxed the stem cells into becoming neural cells, she took clusters of them and put them into a drop of Matrigel. This gave the cells enough support to grow into larger and more complex structures.
Gently shaking the cells in a bioreactor, caused them to specialize into recognizable rudiments of the human brain. Within about two months, the brain organoids had grown structures similar to those found in the human brain, including the cerebral cortex, the seat of human cognition. Organoids also havegenetic similaritieswith the developing human brain. Moreover, many of the neurons in the organoids fired off electrical signals, the messages with which brain cells communicate.
Lancaster immediately realized one of the big promises of brain organoids: As stem cells are their starting material, researchers can take skin samples from adults and re-program those cells into stem cells. These then provide material for a personalized brain organoid. In their first presentation of organoids, the researchers grew personalized organoids from the skin cells of a person with microcephaly. Microcephaly, a condition where the brain is smaller than normal, is difficult to study using mouse models. The researchers took a step toward figuring out why neuron-producing cells stop their job too soon, which could ultimately result in too few neurons. When they added a copy of the faulty gene, the researchers grew organoids with more neuron-producing cells and, ultimately, more nerves.
Brain organoids certainly have their limitations: No two organoids are the same, potentially obscuring differences between personalized organoids. A lack of blood supply keeps the organoids small, as it limits the amount of oxygen that can get into their center. With about a couple of million neurons, a brain organoid has twice as many neurons as a cockroach, but far fewer than an adult zebrafish. Nevertheless, organoids have been used to investigate schizophrenia and autism, and scientists hope to use them to study a range of disorders, from Parkinsons to Alzheimers to eye conditions, like macular degeneration.
With time and intensive research, brain organoids are now better understood and being used in more complex experiments.One studyfound that organoids left to develop for 8 months formed neuronal circuits that sparked with activity, and grew light-sensitive neurons that responded when light was shone on them. Another lab has developedorganoids that produce brain waves similar to those of premature human babies.
Other researchers have developed workarounds to overcome the lack of blood supply. Inanother study, led by Fred Gage, neuroscientists transplanted human brain organoids straight into mouse brains. The organoids connected with the mouses blood supply, and connections between the human organoid and the animals brain sprouted.
This brings up ethical questions: the small blobs of brain tissue arent fully fledged brains, sitting in vats thinking about the meaning of life. The brain waves observed in some mature organoids alone are unlikely to be enough to produce complex brain functions. And, isolated from sensory input,it is unclear whether the organoids could even learn cognitive processes.
But implanting brain organoids into the brain of an actual living mouse could link the blob with the animals senses and motor system. These experiments hark to a related debate raging in science, about the creation and use of chimeras (animals into which human cells have been implanted). While in the US, the National Institutes of Health put in place a moratorium on funding research that investigates animal embryos containing human cells in 2015, in March 2019, Japanannounced a reversal of its ban, allowing scientists to grow human cells in animal embryos that are carried to term.
Arecent perspectivepublished inCellposited that, at the moment, the question isnt whether we humanize an animal into which a human brain organoid is implanted. Instead, it is important to ask whether the organoid enhances specific brain functions in the chimera, and at what point this enhancement crosses the line, becoming harmful and unethical. The authors argue that current studies are more likely to worsen brain function than to improve it.
At the moment, researchers need to make a surgical cavity to accommodate the organoid, which likely harms brain function. Once organoids can make up this deficit, which would be a notable achievement from a clinical perspective, and brain functions are enhanced above a critical threshold, perhaps the chimera should be given a higher moral status. This could go as far as giving the chimera the right of self-determination, the authors argue. Where this critical threshold lies is left open for debate, but the mirror test could be used to test for self-awareness in animals after organoid transplantation.
With brain organoids, the scientific community could be in danger of crossing yet another ethical line, some researchers warn. At this years meeting of the Society for Neuroscience, the largest annual meeting of neuroscientists, a group of scientists sounded the warning bell that research is coming close to creating sentient brain blobs in the lab, while some may have done so already.
The question here is at what point organoids, all on their own, develop consciousness or experience sentiments like pain. In 2018, a group of scientists, lawyers, ethicists, and philosophers, writing inNature,advocated for an ethical debate on brain organoids. With their initiative, they wanted to get ahead of the science, establishing guidelines before brain organoid research could raise immediate concerns.
At the meeting of the Society for Neuroscience, Elan Ohayon, director and founder of the Green Neuroscience Laboratory in San Diego, and his colleagues argued that serious concerns already have become reality. Ohayon presented a computer model which he believes helps to pinpoint when sentience is likely to arise. He suggests that some of the activity seen in organoids is reminiscent of the activity seen in developing animals and thatorganoid cultures may be capable of supporting sentient activity and behavior. Ohayon calls for a set of criteria to be applied to organoids that could help determine sentience and set ethical rules.
Brain organoids likely have a long way to go until they develop consciousness. And there is also likely a long way to go until they help researchers achieve therapeutic benefits. However, the promise of these blobs is so great that giving up brain organoid research altogethergiven the suffering caused by neurological and psychiatric diseases, and the lack of other modelscould itself be unethical. Whether or not any ethical lines have been crossed already, it is high time that neuroscientists, and society, come to terms with the question: What will organoids be able to tell us, and are we prepared to pay the price?
This article originally appeared on JSTOR Daily. Read the original here.
Go here to read the rest:
The ethics of lab-grown "minibrains" - Quartz
- Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update - Yahoo... - November 8th, 2021
- BioRestorative Therapies Prices $23 Million Public Offering - GlobeNewswire - November 8th, 2021
- Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World - Intelligent Living - November 8th, 2021
- Probiotics Market to Experience Significant Growth during the Forecast Period 2021-2028 Bolivar Commercial - Bolivar Commercial - November 8th, 2021
- They demonstrate the existence of stem cells in the hippocampus of the human brain - Market Research Telecast - October 28th, 2021
- BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors - StreetInsider.com - October 28th, 2021
- Akiko Nishiyama Explains the Many Strengths of a Degree in Physiology and Neurobiology - UConn Today - UConn Today - October 28th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- College Student and Retired Teacher to Thank Stem Cell Donors They've Never Met for Saving Their Lives During City of Hope's 45th Bone Marrow... - October 16th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 16th, 2021
- Cell therapy strategies for COVID-19: Current approaches and potential applications - Science Advances - August 18th, 2021
- Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights - PharmiWeb.com - August 18th, 2021
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 18th, 2021
- Atf3 and Rab7b genes drive regeneration in mature cells - Baylor College of Medicine News - August 18th, 2021
- U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT - August 18th, 2021
- Mesenchymal Stem Cells Market Witnesses Upward Trend with High Prevalence of Parkinson's Disease The Manomet Current - The Manomet Current - July 22nd, 2021
- BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -... - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network - April 4th, 2021
- Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News - March 8th, 2021
- Adult Stem Cells Market Size, Share, Global Industry Overview, Challenges, Business Overview and Forecast Research Study 2024 (Effect of the COVID-19... - February 17th, 2021
- Be The Match encourages people of color to join bone marrow registry - KING5.com - February 17th, 2021
- Discovery for turning on cell repair in tissues and organs - Monash University - February 17th, 2021
- Manageable Safety Profile Observed in Phase 1 Studies Examining UCART19 for Pediatric and Adult Patients with B-Cell ALL - Cancer Network - February 11th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 11th, 2021
- JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS - Cancer Network - February 9th, 2021
- Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal - February 9th, 2021
- JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology - February 9th, 2021
- Stem Cells Market Value to Reach Around USD 17.79 Bn by 2027 - GlobeNewswire - February 4th, 2021
- Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News - Jumbo News - February 4th, 2021
- Stem Cell Therapy Market to Score Past US$ 40.3 Billion Valuation by 2027: At a CAGR of 21.1% KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 2nd, 2021
- Reduced Adult Neurogenesis Linked with Alzheimers Disease - The Scientist - February 2nd, 2021
- Regenerative Medicine (Bone and Joint) Market to Score Past US$ 14990.0 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The... - February 2nd, 2021
- Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika... - February 2nd, 2021
- Adult Stem Cells Market Demand, Growth Challenges, Industry Analysis And Forecasts To 2026 | Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell... - February 2nd, 2021
- ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily - February 2nd, 2021
- Medicine by Design researchers focus on promoting self-repair of the brain - News@UofT - January 31st, 2021
- Should You Buy Brainstorm Cell Therapeutics Inc (BCLI) Stock on Tuesday? - InvestorsObserver - January 31st, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 14th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - GlobeNewswire - January 14th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 14th, 2021
- New Models in Organoids Market Open New Vistas in Stem Cell Research for Cancer, Global Valuation to Reach US$ 12.8 Bn by 2030: TMR - PRNewswire - January 12th, 2021
- Health Canada Approves ONUREG (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemia - Canada NewsWire - January 12th, 2021
- Stem Cells Market 2020 Research Study including Growth Factors, Types and Application to 2026| Covid-19 Impact - Farming Sector - January 9th, 2021
- The real reason behind goosebumps - Jill Lopez - January 3rd, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 3rd, 2021
- New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology - January 3rd, 2021
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 26th, 2020
- ElevateBio's HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting - Business Wire - December 6th, 2020
- CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine - December 6th, 2020
- Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo - Science Advances - December 6th, 2020
- UCART22 Safe and Active in CD22-Expressing B-Cell ALLs - Targeted Oncology - December 6th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media - December 6th, 2020
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - GlobeNewswire - November 25th, 2020
- Functionally distinct resident macrophage subsets differentially shape responses to infection in the bladder - Science Advances - November 25th, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization Other OTC:BRTX - GlobeNewswire - November 20th, 2020
- Jakafi and Dacogen May Improve Overall Survival in Patients with MPN - Curetoday.com - November 20th, 2020
- BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) - MicroCap Daily - November 20th, 2020
- As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek - November 16th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 16th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 16th, 2020
- Cynata Therapeutics (ASX:CYP) begins phase three osteoarthritis trial - The Market Herald - November 16th, 2020
- $ 30.1 billion Worth Cell Expansion Market, Led by Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Terumo BCT and Others. re:Jerusalem -... - November 3rd, 2020
- Impact of COVID-19 on Advanced Wound Care Management Market : Implications on Business Strategies, Countermeasures, Economic Impact - The Think... - November 1st, 2020
- Stem Cells Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 - Zenit News - October 30th, 2020
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News - October 30th, 2020
- JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double... - October 29th, 2020
- Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 - PRnews Leader - October 29th, 2020
- APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of... - October 29th, 2020
- Why Small Businesses Matter in Wilton (Reimagined): Interventional Orthopedics Connecticut - HamletHub - October 29th, 2020
- Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |... - October 29th, 2020
- Cell Expansion Market a comprehensive study by key players- Thermo Fisher Scientific, Inc, Becton, Dickinson and Company, Terumo BCT, Merck KGaA and... - October 24th, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 24th, 2020
- What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies? - Targeted Oncology - October 21st, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Eurowire - October 17th, 2020
- Global Stem Cell Therapy Market (Covid-19 updated report), Trends, Top Manufacturers, Exponential Growth and Forecast 2020 to 2027 By Reportspedia -... - October 17th, 2020